Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
Sequencing Therapies in Patients with R/R MM
Drs Cowan and Anderson review whether older agents such as isa-based regimens still have a place in R/R MM treatment after the introduction of bispecific agents and CAR-T therapy.
Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.
CAR-T Therapy in R/R MM Treatment
Key opinion leaders compare the overall benefits of CAR-T therapy and share some advice for managing the toxicities of CAR-T therapy as a patient transitions back to their local doctor.
Available Treatment Options for Relapsed/Refractory Multiple Myeloma
Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.
Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.
Maintenance Therapy in Transplant-Ineligible NDMM
Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.